Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.58 |
| ▸ | RAF1 | P04049 | 3/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 4/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776972 | 0.80 | MAPK14 (0.57) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL5773442 | 0.76 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL5774046 | 0.76 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5773898 | 0.75 | MAPK14 (0.56) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL4024638 | 0.74 | MAPK11 (1.00) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL4587083 | 0.74 | MAPK11 (1.00) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL5776308 | 0.72 | TGFBR1 (0.58) | MAPK14CSNK1DKDM4E | |
| SCHEMBL5771936 | 0.72 | MAPK14 (0.52) | MAPK14MAPK13MAPK9MAPK12MAPK11 | |
| SCHEMBL9857456 | 0.72 | CSNK1A1 (0.75) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL5772341 | 0.71 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370559-B1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6696464-B2 | POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK | PFIZER INC | 2004-02-24 | — | — | US | disclosed |
| EP-1370559-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002072579-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | MAPK1, CNKSR1, JAK1 | MAPK14 15/4885MAPK13 60/4885RAF1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.